Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0375 | 0.0375 |
Echinococcus multilocularis | lamin | 0.0033 | 0.3537 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.3537 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3039 | 0.5 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5545 | 0.5545 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Echinococcus multilocularis | musashi | 0.0033 | 0.3537 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.3039 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.3039 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.3039 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.3039 | 0.3039 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3039 | 0.5 |
Echinococcus granulosus | lamin | 0.0033 | 0.3537 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.3537 | 1 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.3039 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3039 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3397 | 0.3397 |
Brugia malayi | hypothetical protein | 0.003 | 0.3039 | 0.3039 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3039 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.3537 | 0.3537 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.002 | 0.0516 | 0.0516 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.3537 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5545 | 0.5545 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5545 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0562 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.